Hello all. I've been lurking on here since back in 2019

New Post Public Reply Private Reply Replies (2) Message Board
Section
1,013
Hello all. I've been lurking on here since back in 2019 when I first invested in Cytodyn. After realizing that the ad popups now have their own ad popups who brought more ad popups to the party, I decided to make an account hoping they back off, but the same gray haired dudes are smirking at me. I know, I'll look at ad blockers. But, since I created an account, why not say hi and let everyone know that there have been tons of us in the background watching this stock for a while now.

Like the dudes in the ads, I normally have a leery look on most stocks, but even through all the craziness of cydy, I've felt optimism. I'm looking forward to a positive result for the CD12 and future trials. From discussions and reading, the science looks on-point.

Anyways, I don't have much to add right now. Maybe a viewpoint from one of the army of outsiders and lurkers.

AF is a fool and everyone seems to realize that now. His hit-piece didn't even dent the stock price, can't even swell a progress or start a scene or two, but no doubt still an easy tool.

Not sure about MDV, never met him, never touched him, not going to touch him now.

The Bruce / Nader thing, maybe going to only discuss lightly. Though I am not a lawyer, I work with patent/copyright lawyers. I asked them about this whole BP/NP thing, which seems to maybe point to technology created while under contract. Specifically, BP's test kits? Maybe technology disputes over patents or something? Many people use patents/tech innovation only for litigation or wonky strong arm techniques. But, we'll see, I'm too far outside to see in. If I find the exact cause of headaches and can run a test for it, I probably can't sue Tylenol and prevent them from selling their product for headaches. So, it's unlikely that being able to verify the cause of a problem being CCL5/RANTES is going to stop a CCR5 inhibitor drug company from continuing to treat the problem.

Stock manipulation on the OTC sucks. We need to get off of this thing. Mulholland needs to get us out of first gear. I'm sure there's a lot to do, so I can't blame him for not succeeding in doing the most important thing for this company's future outside of approvals. We could probably get better funding on Nasdaq, more stability, better control over short-attacks. Hey, Flash, wanna hear a joke?

These ideas of combination therapy are cool, but let's finish the trials we are doing now first. The crew over at Cytodyn have probably written down every possible application, but that doesn't mean there is time nor money until we finish one and get the label.

Nader as CEO. He's a good salesman and knows enough. Could/should he be replaced? Some people on here mention that he doesn't have the deep medical knowledge of the drug. Is that the job of the CEO? Or is it to get the product to market to sell? As CTO and tech lead, I don't expect my CEO crony to know the intricate details of the software, but I do expect him to know enough to sell the hell out of it. It's absurd to require the CEO to be a specialist in the field. Someone with that knowledge would be better suited as CMO. It's funny to entertain the idea, but let's get serious here. You can't split your time like that... that's academia thinking, mock worthy by the real world. The CEO is CEO, CTO is CTO, CMO is CMO, and COO locks up the building for the night.

Future stock price, successes, and failures. If I could successfully forecast these things, I would be a trillionaire. I'm just hanging in there long-term.

FDA for small companies. Unless your job is directly giving them a hand or putting money into their drawers, you probably don't have much sway. You gotta be dirty to hang with that filthy, corrupt bunch. Let's see if the Philippines are more accepting.

I guess that's all for now. Let's see how the results go. Hopefully news soon.

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Red-Eye Flights Surge, Driven By Western U.S. Routes

Updated Category News Views 5

You can always count on some things staying the same, right? Well, if you thought red-eye flights were going to fade away, think again. These late-night wonders are not just hanging around—they're booming in the west like there's no tomorrow. Literally. Champion Traveler has laid it all out for us: about 115,580 overnight flights in 2025, a record high since this mad...

Continue Reading
Veteran Marketer Joins The Wisory's Advisory Board

Updated Category News Views 3

Tyrrell Schmidt Joins The Wisory's Board Out of the blue, The Wisory has snatched Tyrrell Schmidt right off the retirement bench. This doesn't seem like just another board seating; it smells like a calculated power play. Schmidt, fresh from her heavyweight stint as Global CMO at TD Bank, adds a spicy dose of marketing prowess to The Wisory's already loaded Advisory Board....

Continue Reading
Atli Launches: AI-Powered eSIM Revolutionizes Travel

Updated Category News Views 5

What's New in Travel Tech: Atli's Debut Wandering the globe might sound romantic until you realize your phone's a paperweight without the right data. Enter Atli, a shiny new AI-powered travel eSIM service, snugged right into your WhatsApp. This marvel comes from the folks at XForge Mobile and aims to obliterate the hassle of getting connected abroad. You know those...

Continue Reading
Rare Collectibles Highlight Morphy's Auction on Oct 4

Updated Category News Views 2

Anticipation Builds for Morphy's Auction Event Morphy's upcoming event on October 4th is all about tapping into the era of revved engines, gleaming gasoline signs, and some history that could put Hollywood tales to shame. The auction isn't just a stroll down memory lane; it features over 650 lots, each a time capsule of America's automotive past. From Al Capone's ritzy...

Continue Reading
K-9 Hero Act Aims to Ease Costs for Retired Dogs' Care

Updated Category News Views 7

Let's Talk About the Loyalty that Dogs Deserve Who would've thought we'd be chatting about our four-legged heroes in a federal setting? But here we are, giving well-deserved attention to those furry federal agents. They're the ones who sniff out bombs and tackle crooks, and they're not asking for a retirement plan with a yacht – just some vet care! What the K-9 Hero Act...

Continue Reading
AbbVie's Bold Leap in Menstrual Migraine Treatment

Updated Category News Views 10

AbbVie's Game-Changing Atogepant Study When it comes to pushing boundaries in the pharmaceutical world, there's no sitting on the fence. AbbVie's Phase 3 LUNA study results are painting a bright picture for women who suffer from the relentless grip of menstrual migraines. In a world where not a single treatment option has been approved specifically for this condition,...

Continue Reading
CrossCountry Mortgage Boosts Loan Limits, Flexibility for 2027

Updated Category News Views 13

Trailblazing in the Mortgage Game Well, what do we have here? CrossCountry Mortgage, the big cheese of retail mortgage lenders, is cranking up their conforming loan limits to a hefty $845,000. They're jumping the gun on the Federal Housing Finance Agency's official 2027 announcement. It's a classic move—proactive, bold, and a bit of a gamble, if you ask me. They’re...

Continue Reading
RTI's $14M Boost: A Game-Changer for Tech Innovators

Updated Category News Views 6

Breaking Ground in Tech Deployment The march toward commercializing new tech can be a nightmare. Ask any innovator trying to leap from lab genius to market ready, and they'll tell you the pathway is paved with hurdles—especially in the rough-and-tumble world of energy and industrial tech. RTI International's latest $14 million move? That's a massive step in leveling the...

Continue Reading
Havoc, CSBC Partner for Autonomous Maritime Future

Updated Category News Views 6

A Strategic Move Across the Pacific Well, folks, in an era where the seas aren't just blue but powered by tech-backed autonomy, here's a new chapter—the kind that doesn't just hint at innovation, it screams it. Havoc, that crafty leader in all things autonomous, inked a game-changing deal with Taiwan's shipbuilding behemoth, CSBC Corporation. They're not just building...

Continue Reading
Moore Law Investigates Aardvark Therapeutics' Risks

Updated Category News Views 2

Moore Law Launches Probe Into Aardvark Therapeutics Nobody likes stumbling across bad news over their morning coffee, but sometimes the market loves to keep you on your toes. Now it's Aardvark Therapeutics (NASDAQ: AARD) in the headlines, and not how they'd like. This time, Moore Law PLLC is rolling up its sleeves to dig into potential misconduct by the company's top...

Continue Reading

Top 5 Most Recently Viewed Articles

Teleflex's Strategic Move: Separation Into Two Distinct Firms

Updated Category News Views 391

Teleflex's Strategic Separation Initiative In a significant move to enhance shareholder value, Teleflex Incorporated (NYSE: TFX) plans to separate its business into two independent publicly traded entities. This decision follows a comprehensive evaluation of its business portfolio, and the aim is to streamline operations while focusing on core markets. Creating NewCo and...

Continue Reading
Discover the Impressive Returns from Boston Scientific Stock

Updated Category News Views 58

Understanding Boston Scientific's Market Performance Boston Scientific (NYSE: BSX) has been a standout performer in the stock market over the past decade, boasting a remarkable annualized return. Investors who have placed their faith in this innovative medical technology company would be pleased with the results, having realized an annualized growth of 22.01%, which...

Continue Reading
Investigation into Potential Securities Issues at Paysafe Ltd

Updated Category News Views 170

Key Investigation Details on Paysafe Limited Recent developments have brought Paysafe Limited into the spotlight as a law firm initiates an investigation regarding potential securities fraud on behalf of investors. This scrutiny centers on whether the company and its senior management may have breached federal securities laws or engaged in questionable business practices....

Continue Reading
Latham & Watkins' Strategic Moves Spark Asian Market

Updated Category News Views 17

Setting the Stage for Expansion When you hear that Grace Huang and Edward Freeman are hopping onto Latham & Watkins' Hong Kong ship, it's a bit like watching heavyweights enter the ring. Both these pros are bringing a truckload of experience into one of Asia's most competitive markets. This isn't just a small change; it’s a pretty big deal for the firm's capital markets...

Continue Reading
Novele's Groundbreaking Certification for Energy Storage Solutions

Updated Category News Views 189

Novele Achieves Certification Milestone Novele, Inc. has made strides in the energy storage sector by securing important certifications for its innovative EnergyBoard product. These certifications, including Large-Scale Fire Burn VOC, ETL, and CB, highlight the product's compliance with key standards for entry into both North American and European markets. A Memorable...

Continue Reading